ME 23ANDME HLDG CO

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

-14 percent of those surveyed say they’re stressed, compared to more than 47 percent in 2020

-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down from 62 percent in 2020

-However, most respondents still have some concern about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health

SUNNYVALE, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported survey results on how US adults are feeling about their health this holiday season. According to the survey*, most people in the US report feeling less stressed or anxious about their health this year compared to earlier in the pandemic, and many have returned to their traditional holiday celebrations.

In this third holiday under the shadow of COVID-19, people appear to have adjusted to the new normal and are more optimistic about their health.

However, most people are still concerned about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health.

Other highlights from the survey include:

  • 14% of those surveyed said they were more stressed this year compared to last, compared to more than 47% in 2020**
  • Similarly, only about 5% of those surveyed said they were more depressed this year compared to last year, compared to almost 32% in 2020
  • The percentage of respondents who feel less connected to friends and family dropped from 48% in 2020 to just 5% in 2022
  • Only about 17% of those surveyed said they would not be having a traditional holiday this year, compared to 62% in 2020
  • Almost 50% of the respondents who said they’re focused on their health also said they planned to make healthy lifestyle changes in the new year, with a focus on their diet and weight

More details can be found on the .

Methodology

*This online survey was designed by 23andMe and conducted through SurveyMonkey® from November 8th-9th, 2022 among a national sample of 1,109 adults ages 18 and up. Respondents for this survey were selected from people who take surveys on the SurveyMonkey platform each day. Data for this time period have been weighted for age, race, sex, education, and geography using the Census Bureau’s American Community Survey to reflect the demographic composition of the United States. The modeled error estimate for this survey is plus or minus 3.5 percentage points.

**23andMe commissioned a .

About 23andMe

23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit .

Contacts

Investor Relations Contact:

Media Contact:



EN
01/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibo...

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial ev...

 PRESS RELEASE

23andMe Launches New Feature Connecting Customers to Historical Indivi...

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migration SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individuals, from med...

 PRESS RELEASE

23andMe Launches New Genetic Reports on Common Forms of Cancer

23andMe Launches New Genetic Reports on Common Forms of Cancer 23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMe SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores (P...

 PRESS RELEASE

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncol...

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathway SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today anno...

 PRESS RELEASE

23andMe Reports Third Quarter Fiscal 2024 Financial Results

23andMe Reports Third Quarter Fiscal 2024 Financial Results Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch